No Data
Institutions Own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares but Retail Investors Control 46% of the Company
ProQR Announces Presentation on Its Axiomer RNA Editing Technology at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it
Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital